Compare Ishares Msci Brazil ETF (EWZ) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Brazil ETF vs Recursion Pharmaceuticals Inc — how do they compare? Ishares Msci Brazil ETF trades at $43.01 (market cap $11.30B), while Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B). The key difference: Ishares Msci Brazil ETF is far larger — about 5.3× Recursion Pharmaceuticals Inc's market cap, and Ishares Msci Brazil ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Brazil ETF for 50 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| EWZ | RXRX | |
|---|---|---|
Market Cap | $11.30B | $2.14B |
Volume | 44,036,597 | 30,789,535 |
Sector | Broad Market / Factor | Health |
52-Week High | $43.00 | $6.79 |
52-Week Low | $28.79 | $2.84 |
Typical Hold Time | 50 Days | 22 Days |
Enterprise Value | — | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWZ, the iShares MSCI Brazil ETF, trades at $42.37, down 1.47% today. The technical outlook is mixed with moving averages signaling bullish momentum but oscillators showing bearish pressure, including overbought RSI readings. Recent news highlights significant investor focus on Brazil's upcoming October election, with unusual options activity and institutional positioning suggesting anticipation of market-moving outcomes. The ETF serves as a key diversifier for U.S. investors seeking exposure to Brazilian equities and commodities.
The outlook for EWZ is heavily tied to Brazilian political and economic developments, particularly the election outcome. While technical indicators show conflicting signals, the substantial options volume and institutional interest indicate heightened expectations for volatility. Key risks include election uncertainty and U.S.-Brazil trade tensions, but potential rate cuts and commodity exposure offer upside for diversified portfolios.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
